ClinicalTrials.gg
Status unknownNCT05646745Updated Aug 15, 2024

Autologous Transobturator Fascia Lata Sling in Treatment of Female Stress Urinary Incontinence

An interventional study of Autologous Transobturator Fascia Lata Sling in Stress Urinary Incontinence, sponsored by Al-Azhar University. Status unknown at 2 sites in Egypt. Open to female participants. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2024), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jan 2022, registered Dec 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Sex
Female
01

Study summary

To evaluate the outcome of autologous transobturator fascia lata sling for treatment of female stress urinary incontinence at Al-Azhar university hospitals.

Read the detailed description

Following induction of anesthesia and administration of perioperative antibiotics, the patient is positioned in the dorsal lithotomy position, sterilization and draping will be done. A sterile 16 French Foley catheter is placed to drain the bladder, following this, injectable normal saline is utilized using 10 cc syringe for hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.

Through incision in the lower lateral aspect of the thigh, 4 cm above the knee, \~1 cm× \~5 cm fascial strip is isolated from the fascia lata. Two stay sutures are secured to the corners of the fascial segment on each side.

About 1cm skin incision is performed at the thigh fold on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration of the fascial strip.

02

Conditions studied

  • Stress Urinary Incontinence

Keywords

  • Autologous
  • TOT
  • SUI
  • Stress
03

In context

Urinary Incontinence, Stress

671 studies on the registry are indexed under Urinary Incontinence, Stress; 122 are open to participants now.

This study's planned enrollment of 60 is below the median of 69 across 520 interventional studies indexed under Urinary Incontinence, Stress.

Browse Urinary Incontinence, Stress studies →

Lead sponsor

Al-Azhar University is the lead sponsor of 525 studies on the registry; 171 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with genuine stress urinary incontinence.
  • Mixed urinary incontinence with predominant stress element.
  • Refractory cases to conservative therapy or patients who are not willing to consider (further) conservative treatment.

Exclusion criteria

Exclusion Criteria:

  • Mixed incontinence with predominant Urge urinary incontinence.
  • Associated local abnormalities that may affect surgery outcomes (e.g. complete procidentia).
  • Recent or active urinary tract infection.
  • Recent pelvic surgery.
  • Neurogenic lower urinary tract dysfunction.
  • Previous surgery for stress urinary incontinence.
  • Pregnancy
  • Less than 12 months post-partum.
  • Other gynaecologic pathologies affecting bladder functions ( eg, large fibroids, ovarian cysts)
  • Genito-urinary malignancy.
  • Current chemo or radiation therapy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Autologous Fascia lata TOT

    Through incision in the lower lateral aspect of the thigh, 4 cm above the knee, \~1 cm× \~5 cm fascial strip is isolated from the fascia lata. Two stay sutures are secured to the corners of the fascial segment on each side. About 1cm skin incision is performed at the thigh fold on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration of the fascial strip.

    Procedure: Autologous Transobturator Fascia Lata Sling

Interventions

  • ProcedureAutologous Transobturator Fascia Lata Sling

    Hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides. Through incision in the lower lateral aspect of the thigh, 4 cm above the knee, \~1 cm× \~5 cm fascial strip is isolated from the fascia lata. Two stay sutures are secured to the corners of the fascial segment on each side. About 1cm skin incision is performed at the thigh fold on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration of the fascial strip.

06

What researchers measure

Primary outcomes

  1. complete cure

    Number of patients without leakage with cough stress test and the patient is satisfied and on examination there is no leakage with cough test.

    Time frame: 3 months

Secondary outcomes

  1. improvement of SUI

    Number of patients who report leakage only with severe exertion and using a smaller number of pads per day and she feels that she has improved. On examination there is no stress urinary incontinence.

    Time frame: 3 months

07

Study locations

2 of 2 sites recruiting
  • Mohamed Fawzy Salman
    Cairo, Egypt
    Recruiting
  • Urology department - AlAzhar university
    Cairo, Egypt
    Recruiting
08

References and documents

Publications

  • Salman MFA, Hassan AA, Wasfy IS, Deif H, Hassan AA, Hindawy MA, Hassan AMA, Ali MM, Abdel-Al I, Koritenah AK, Abuelazayem TM, Keritna HKM. Autologous Transobturator Fascia Lata Sling for Female Stress Urinary Incontinence: A Pilot Feasibility and Safety Study. Low Urin Tract Symptoms. 2026 Sep;18(5):e70085. doi: 10.1111/luts.70085. PubMed 42521462 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05646745
Responsible party
Mohamed Fawzy Abd Elfattah Salman (Director, Al-Azhar University) — Principal investigator
First posted
Dec 12, 2022
Start date
Jan 1, 2022
Primary completion
Oct 1, 2025 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Aug 15, 2024

Study contacts

Mohamed F Salman, MD
Contact
Prof_mohamed_fawzy@yahoo.com
00201111788996

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion